SAP SE

  • WKN: 716460
  • ISIN: DE0007164600
  • Land: Deutschland

Nachricht vom 19.12.2011 | 17:58

SAP AG: Release according to Article 30e of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution


SAP AG  / Third country release according to Article 30e Para. 1, No. 3
of the WpHG [the German Securities Trading Act]

19.12.2011 17:58

Dissemination of a Post-admission Duties announcement according to Article
30e Para. 1 No. 3 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------


With ad hoc announcement dated December 3, 2011 SAP AG ('SAP') announced
that SAP's subsidiary, SAP America, Inc., has entered into a definitive
merger agreement with SuccessFactors, Inc. ('SuccessFactors') pursuant to
which a subsidiary of SAP would offer to acquire all outstanding shares of
common stock of SuccessFactors. In connection with this merger agreement,
SAP has filed on December 16, 2011 with the U.S. Securities and Exchange
Commission (SEC) a Schedule TO-T containing the offer to purchase, letter
of transmittal and other documentation pertaining to its offer to purchase
all outstanding shares of common stock of SuccessFactors.

The documentation filed on December 16, 2011 comprises the following:

A Schedule TO-T including 
- 'Exhibit (a)(1)(A) - Offer to Purchase dated December 16, 2011' 
- 'Exhibit (a)(1)(B) - Form of Letter of Transmittal'
- 'Exhibit (a)(1)(C) - Notice of Guaranteed Delivery'
- 'Exhibit (a)(1)(D) - Form of Letter to Brokers, Dealers, Commercial
Banks, Trust Companies and Other Nominees'
- 'Exhibit (a)(1)(E) - Form of Letter to Clients for Use by Brokers,
Dealers, Commercial Banks, Trust Companies and Other Nominees'
- 'Exhibit (a)(1)(F) - Guidelines for Certification of Taxpayer
Identification Number on Substitute Form W-9'
- 'Exhibit (a)(5)(A) - Press release issued by SAP AG and SuccessFactors on
December 3, 2011 incorporated herein by reference to the Form 6-K furnished
by SAP AG, SAP America and the Purchaser on December 5, 2011'
- 'Exhibit (a)(5)(B) - Summary Advertisement as published in the Wall
Street Journal on December 16, 2011'
- 'Exhibit (a)(5)(C) - Press release issued by SAP AG on December 16, 2011'
- 'Exhibit (b)(1) - Euro 1 billion Credit Facility Agreement dated December
3, 2011, among SAP AG, as borrower, J.P. Morgan Limited as mandated lead
arranger, the financial institution listed in Schedule 1 as original
lender, and J.P. Morgan Europe Limited, as agent'
- 'Exhibit (d)(1) - Agreement and Plan of Merger dated as of December 3,
2011 by and among SAP America, the Purchaser and SuccessFactors
incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K
filed by SuccessFactors on December 5, 2011'
- 'Exhibit (d)(2) - Mutual Non-Disclosure Agreement effective as of October
20, 2011 between SAP AG and SuccessFactors'
- 'Exhibit (d)(3) - Exclusivity Agreement dated as of November 9, 2011
between SAP AG and SuccessFactors'
- 'Exhibit (d)(4) - Amended and Restated Exclusivity Agreement dated as of
November 22, 2011 between SAP AG and SuccessFactors'
- 'Exhibit 99.2 - Power of Attorney'

These documents are available on the website of SAP AG under 
http://www.sap.com/corporate-en/investors/successfactors/offer.epx.



19.12.2011 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      SAP AG
              Dietmar-Hopp-Allee 16
              69190 Walldorf
              Germany
Internet:     www.sap.com
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------

GBC-Research im Fokus

amp biosimilars AG: Am Anfang einer steilen Wachstumskurve

Mit dem Fokus auf der Entwicklung von Biosimilars adressiert die amp biosimilars AG einen der am stärksten wachsenden Teilbereiche der Pharmabranche. Haupttreiber sind hier die zahlreichen Patentausläufe sowie die hohe Nachfrage nach kostengünstigen Arzneien. Die amp biosimilars AG ist mit ihrem Plattform-Ansatz in der Lage, Biosimilars günstiger, effizienter und schneller zu entwickeln, als es bisher möglich war. Mit der frühzeitigen Auslizenzierung der ersten beiden Projekte wurde bereits der Proof of Concepts erbracht. Wir erwarten den Ausbau der Projektpipeline und haben einen fairen Wert je Aktie von 40,30 € („KAUFEN“) ermittelt.

News im Fokus

Operatives Ergebnis im ersten Halbjahr 2015 auf über 1 Mrd. Euro gesteigert

03. August 2015, 07:07

Aktueller Webcast

Hypoport AG

Halbjahreszahlen 2015

03. August 2015

Aktuelle Research-Studie

Nemetschek AG

Original-Research: Nemetschek AG (von Montega AG): Halten

31. Juli 2015